Prescribing Information - Refer to SPC before prescribing

MENVEO® powder and solution, for injection. Meningococcal group A, C, W135 and Y conjugate vaccine. **Indications:** Active immunisation against *Neisseria meningitidis* serogroups A, C, W135 and Y for children (from 2 years of age), adolescents and adults. **Dosage:** a single dose of 0.5 ml into the deltoid muscle. Separate injection sites should be used if administering more than one vaccine. **Booster vaccination:** Refer to SPC and national recommendation. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients, or diphtheria toxoid (CRM_{197}). Postpone use in persons with acute, severe febrile illness. **Precautions:** See SPC for advice on use in immunocompromised individuals. Dizziness has rarely been reported after vaccination which may temporarily affect the ability to drive or use machines. **Interactions:** see SPC. **Pregnancy and Lactation:** Insufficient clinical data on exposed pregnancies are available. **Adverse reactions:** See SPC for full details. *Very Common/Common*: sleepiness, headache, nausea, irritability, malaise, injection site pain, injection site erythema (≤50 mm), injection site induration (≤50 mm), myalgia, arthralgia, injection site erythema (>50mm), injection site induration (>50mm), chills, fever ≥38°C.

Serious: hypersensitivity including anaphylaxis, convulsions, injection site cellulitis. **Legal Category:** POM. **Presentation and basic NHS cost:** Pack of two vials. MENVEO® must be prepared for administration by reconstituting powder (in vial) with solution (in vial), £30.00 per dose. **MA Holder:** GSK Vaccines S.r.l., Via Fiorentina 1, 53100 Siena, Italy. **MA Number:** EU/1/10/614/002, EU/1/10/614/003. Further information is available from Customer Contact Centre, GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BT; customercontactuk@gsk.com; Freephone: 0800 221 441. **Date of preparation:** February 2017 UK/MEN/0003/17

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.